| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Arteannuin B targets multiple pathways involved in malaria, cancer, inflammation, and viral infection. As a precursor in artemisinin biosynthesis, it shares similar antimalarial mechanisms. The compound selectively targets cancer cells by inducing apoptosis and inhibiting cell proliferation, particularly in breast, lung, and liver cancers. It enhances immune responses and modulates several signaling pathways, including NF-κB and MAPK. Arteannuin B has anti-SARS-CoV-2 activity.
|
|---|---|
| ln Vitro |
In vitro, Arteannuin B has potent antimalarial activity with an IC50 value of 0.2 nM. It exhibits anti-cancer, anti-inflammatory, and anti-viral properties. The compound selectively targets cancer cells by inducing apoptosis and inhibiting cell proliferation. Arteannuin B shows anti-SARS-CoV-2 activity with an EC50 of 10.28 μM. It is soluble in DMSO (100 mg/mL, 402.71 mM, need ultrasonic). The compound's anticancer and anti-inflammatory activities have been characterized in various cell-based assays.
|
| ln Vivo |
In vivo, Arteannuin B has demonstrated potent antimalarial activity. It selectively targets cancer cells by inducing apoptosis and inhibiting cell proliferation. The compound enhances immune responses and modulates several signaling pathways, including NF-κB and MAPK. Arteannuin B has been studied in animal models for its antimalarial, anticancer, anti-inflammatory, and antiviral effects. Further in vivo studies are ongoing to fully characterize its therapeutic potential. The compound is typically administered orally or via injection in preclinical studies.
|
| Enzyme Assay |
Arteannuin B antimalarial assays involve measuring inhibition of Plasmodium growth. Malaria parasites are cultured in appropriate media and treated with Arteannuin B at varying concentrations. Antimalarial activity is assessed by measuring parasite growth inhibition and IC50 determination (0.2 nM). Anti-cancer activity is evaluated by assessing inhibition of cancer cell proliferation or induction of apoptosis in cancer cell lines. Anti-inflammatory activity is measured by assessing inhibition of pro-inflammatory cytokine production. Anti-SARS-CoV-2 activity is assessed by measuring viral replication inhibition (EC50 = 10.28 μM). Assays are performed with appropriate positive controls.
|
| Cell Assay |
Arteannuin B cell-based assays are conducted in cancer cell lines, immune cells, and virus-infected cells. Cells are cultured in appropriate media at 37°C with 5% CO2 and treated with Arteannuin B at varying concentrations. Cell viability is assessed by MTT or CCK-8 assays. Apoptosis is evaluated by Annexin V/PI staining and caspase activity assays. Inflammatory markers are measured by ELISA. For antiviral studies, virus-infected cells are treated with the compound and viral replication is measured. Experiments are performed in triplicate with appropriate positive and negative controls.
|
| Animal Protocol |
Arteannuin B in vivo studies are conducted in animal models of malaria, cancer, inflammation, and viral infection. Animals are treated with Arteannuin B via oral administration or injection. For antimalarial studies, Plasmodium-infected mice are used and parasitemia is monitored. For anti-cancer studies, tumor-bearing mice are used and tumor growth is monitored. For anti-inflammatory studies, animal models of inflammation are used. For antiviral studies, virus-infected animal models may be used. Dosing regimens are optimized based on pharmacokinetic data. Animals are monitored for clinical signs. Tissues and blood samples are collected for histopathological and biomarker analysis.
|
| ADME/Pharmacokinetics |
Arteannuin B (MW 248.32 g/mol, C15H20O3) is a natural sesquiterpenoid. It is soluble in DMSO (100 mg/mL, 402.71 mM, need ultrasonic). The compound is stable under recommended storage conditions. Arteannuin B is a precursor in the biosynthesis of artemisinin and co-exists with artemisinin in Artemisia annua. Pharmacokinetic parameters such as half-life, bioavailability, and tissue distribution would be determined in species-specific studies. The compound is typically used in antimalarial, anticancer, and antiviral research.
|
| Toxicity/Toxicokinetics |
Arteannuin B is generally well-tolerated in preclinical studies at therapeutic doses. The compound is a natural sesquiterpenoid from Artemisia annua with a well-characterized safety profile. Its antimalarial, anticancer, anti-inflammatory, and antiviral activities have been demonstrated with acceptable safety profiles. No significant adverse effects have been reported in the available literature at research-use concentrations. The compound is intended for research use only. Standard safety precautions should be followed when handling. Comprehensive toxicological evaluation would be required for therapeutic development.
|
| References | |
| Additional Infomation |
Reports indicate that Artemisia annua, Artemisia argyi, and Artemisia umbellata contain artemisinin B, and relevant data is available for reference.
Arteannuin B is a natural sesquiterpenoid from Artemisia annua and a precursor in artemisinin biosynthesis. It has potent antimalarial activity (IC50 = 0.2 nM) and anti-SARS-CoV-2 activity (EC50 = 10.28 μM). The compound selectively targets cancer cells by inducing apoptosis and inhibiting proliferation, particularly in breast, lung, and liver cancers. It enhances immune responses and modulates NF-κB and MAPK pathways. All applications are limited to non-human research use. |
| Molecular Formula |
C15H20O3
|
|---|---|
| Molecular Weight |
248.3175
|
| Exact Mass |
248.141
|
| CAS # |
50906-56-4
|
| PubChem CID |
6543478
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
398.7±35.0 °C at 760 mmHg
|
| Flash Point |
168.5±20.5 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.549
|
| LogP |
1.91
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
18
|
| Complexity |
457
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
C[C@@H]1CC[C@H]2C(=C)C(=O)O[C@]23[C@H]1CC[C@@]4([C@H]3O4)C
|
| InChi Key |
QWQSMEDUZQDVLA-KPHNHPKPSA-N
|
| InChi Code |
InChI=1S/C15H20O3/c1-8-4-5-11-9(2)12(16)17-15(11)10(8)6-7-14(3)13(15)18-14/h8,10-11,13H,2,4-7H2,1,3H3/t8-,10+,11+,13-,14-,15-/m1/s1
|
| Chemical Name |
(1R,5S,8R,9S,12R,14R)-8,12-dimethyl-4-methylidene-2,13-dioxatetracyclo[7.5.0.01,5.012,14]tetradecan-3-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~100.68 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1 mg/mL (4.03 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1 mg/mL (4.03 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1 mg/mL (4.03 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0271 mL | 20.1353 mL | 40.2706 mL | |
| 5 mM | 0.8054 mL | 4.0271 mL | 8.0541 mL | |
| 10 mM | 0.4027 mL | 2.0135 mL | 4.0271 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
